CLAIMS

It has been described and exemplified the nature and the main objective of the present invention, and also the advantages upon other medicaments used at present for the same disease; as well as the way in which the invention can be put into practice, it is hereby claimed the ownership and the exclusive legal rights: —

1.- A PHARMACEUTICAL COMPOUND FOR THE MEDICAL TREATMENT OF THE BENIGN PROSTATE HYPERPLASIA, duly <u>characterized because</u> it is a Pharmaceutical Composition in which each 1 ml. contains:

Polysaccharides of Gram Negative Bacteria:	between	0,05 gr. y 0,002 gr.
Thymus (hydro soluble extract) :	between	2 mg. & 0,1 mg.
Prostate (hydro soluble extract):	between	1 mg. & 0,0l mg.
Total Carbo hydrates (Glucose):	between	2 mg.& 0,02 mg.
Physiologic solution (bacteria free) : s. q. f		1 ml.

- 2.- A PHARMACEUTICAL COMPOUND FOR THE MEDICAL TREATMENT OF THE BENIGN
 PROSTATE HYPERPLASIA, according to claimed in 1, duly <u>characterized because</u> the
 Polysaccharide is a Polysaccharide of Pseudomonas Aeruginosa in the indicated proportions.
- 3.- A PHARMACEUTICAL COMPOUND FOR THE MEDICAL TREATMENT OF THE BENIGN PROSTATE HYPERPLASIA, according to claimed in 1, duly <u>characterized because</u> the Compound contains each 1 ml:

Polysaccharide of Pseudomonas Aeruginosa:	0,005 gr.
Thymus (hydro soluble extract)	0,9 mg.
Prostate (hydro soluble extract)	0,3 mg.
Total Carbo hydrates (Glucose):	0.038 ma

Physiologic solution	(bacteria free): s	s. q.	f	1 n	nl.
----------------------	--------------------	-------	---	-----	-----

4.- THE PREPARATION METHOD of the composition claimed in 1, duly characterized because includes an appropriate method to culture Pseudomonas bacteria in the following conditions:
a) the culture of the mentioned polysaccharide is performed in a liquid medium in the same specialized manner as it is usually done, taking always into consideration that work must be carried out under the most rigorous conditions of bacteriological asepsis.
b) It is necessary to obtain an appropriate stock, previously typified with the corresponding

biochemical tests.

- **5.- PREPARATION METHOD,** according to claimed in 4, duly <u>characterized because</u> the culture stock to use, will be chosen among the nutritious cultured broths which are available at laboratories producing commercial bacteriological products.
- **6.- PREPARATION METHOD**, according to claimed in 4, duly <u>characterized because</u> it is essential to establish the Bacteria Growing Curves in order to know the optimum culture time to obtain thereafter a high concentration of polysaccharide.
- **7.- PREPARATION METHOD,** according to claimed in 4, duly <u>characterized because</u> the resulting bacterial mass will be carefully washed and conditioned. After been weighed, bacteria will be stored in freezer until they are needed.
- **8.- PREPARATION METHOD**, according to claimed in 4, duly <u>characterized because</u> in all cases the corresponding bacteriological control of the stock will be performed through specific biochemical

tests in order to ensure they are bacteria free.

9.- PREPARATION METHOD, according to claimed in 4, duly <u>characterized because</u> the bacterial mass must be conditioned first to then carry on to its extraction, using techniques with organic solvents.

Thereafter the mass is duly dried and weighed. To weigh the bacteria the culture broth must be ultra-air- centrifuged in order to discard the leftovers.

10.- PREPARATION METHOD, according to claimed in 4, duly characterized because we proceed to weigh the tare which is obtained weighing the difference between the empty jar (previously weighed) and the jar with bacterial sediment. Thereafter, a phenol solution is prepared in optimum concentration in order to obtain the maximum efficiency and then, we must use the liquid phase but discarding the bacterial remnants. Finally, we proceed to the separation of the lipoid fraction to obtain the pure polysaccharide (desensitizer haptene). To such effects we utilize hydrolysis to eliminate the toxic fraction (lipoid) and then it must be ultra centrifuged to finally obtain the polysaccharide in its state of highest purity. To lyophilize.

11.- THERAPEUTIC APPLICATION FOR THE MEDICAL TREATMENT OF BENIGH PROSTATIC

HYPERPLASIA, duly characterized because it consists in the use of a Pharmaceutical Compound in which each 1 ml. contains

Polysaccharides of Gram Negative Bacteria: between 0,05 gr. & 0,002 gr.

Thymus (hydro-soluble extract). between 2 mg. & 0,1 mg.

Prostate (hydro- soluble extract): between 1 mg. & 0,01 mg.

Total Carbo Hydrates (Glucose): between 2 mg. & 0,02 mg.

Bacteria free physiologic Solution: s. q.f. 1 ml.

12.- THERAPEUTIC APPLICATION, according to claimed in 11, duly <u>characterized because</u> the Composition contains each 100 ml.:

Polysaccharide of Pseudomonas Aeruginosa	0,005	gr.
Thymus (hydro-soluble extract) :	0,9	mg.
Prostate (hydro-soluble_extract)	0,3	mg.
Carbo hydrates (Glucose):	0,0	38 mg.
Bacteria free physiologic solution: s. q. f	1 ml	

Hipólito Carmelo María BARREIRO

SUMMARY:

1.- A PHARMACEUTICAL COMPOUND FOR THE MEDICAL TREATMENT OF THE BENIGN

PROSTATE HYPERPLASIA, duly <u>characterized because</u> it is a Pharmaceutical Composition in which each 1 ml. contains:

Polysaccharides of Gram Negative Bacteria:	between	0,05 gr. y 0,002 gr.
Thymus (hydro soluble extract) :	between	2 mg. & 0,1 mg.
Prostate (hydro soluble extract):	between	1 mg. & 0,0l mg.
Total Carbo hydrates (Glucose):	between	2 mg.& 0,02 mg.
Physiologic solution (bacteria free): s. q. f	•••••	1 ml.

11 claims follow.